As an undisputed world-leading service provider, Creative Biolabs is professional in discovery and development of in vitro diagnostic (IVD) antibodies. Based on years of experience, vast expertise, and advanced platform, we offer world-class IVD antibody services to generate antibody (pairs) with the best quality and high specificity.

PD-L1: General Description

Encoded by the PDCDL1 gene, programmed death ligand 1 (PD-L1) is regarded as the third member of the B7 protein family. As a type 1 transmembrane protein, PD-L1 is composed of a hydrophobic transmembrane domain, IgV-like, and IgC-like extracellular domains, and a short cytoplasmic tail made from 30 amino acids. PD-L1 is a coinhibitory receptor constitutively expressed or induced in lymphoid, myeloid, normal epithelial cells and in cancer. Overexpression of PD-L1 is common on tumor cells or on non-transformed cells in the tumor microenvironment and its binding to PD-1 receptors on the activated T cells leads to the inhibition of the cytotoxic T cells. The expression of PD-L1 in cancer is an immune evasion mechanism exploited by various malignancies and is generally associated with poorer prognosis. Its expression is also demonstrated as a predictive biomarker of response to anti-PD-1/PD-L1 therapies.

A schematic representation illustrating the signalling molecules that are linked with or influenced by the programmed death 1 (PD-1)/ programmed death ligand 1 (PD-L1) interaction. Fig.1 A schematic representation illustrating the signalling molecules that are linked with or influenced by the programmed death 1 (PD-1)/ programmed death ligand 1 (PD-L1) interaction. (Kythreotou, A., 2017)

PD-L1 as a Biomarker for Lung Cancer

Immunotherapies targeting PD-1/PD-L1 have improved survival rates in a subset of patients with advanced lung cancer. Biomarkers play a significant role in directing the rational use of PD-1/PD-L1 checkpoint inhibitors. The expression level of PD-L1 protein has emerged as a biomarker to predict the patients who are more likely to respond to immunotherapy. Besides, a general trend has been shown across studies that increased response to PD-1/PD-L1 inhibitors are associated with the increasing PD-L1 expression, although the strength has been variable. In summary, PD-L1 is a predictive biomarker of treatment efficacy and the evaluation of the PD-L1 expression is an integrated biomarker which has been incorporated in all key studies of this class of agents in advanced NSCLC. PD-L1 has been served as the high-efficient marker for the diagnosis of lung cancer and shows the potential target for the therapy.

IVD Antibody Development Service Targeting PD-L1 Marker

IVD antibodies have been used as essential elements in immunoassays such as immunonephelometry and sandwich ELISA to detect elevated biomarkers in various biological samples for disease screening and therapeutic monitoring. As a result, the development of antibodies with both high specificity and affinity to target molecules is of great importance. Creative Biolabs has accumulated years of experience in the antibody development with the accomplishment of various challenging projects. With our versatile IVD platform, Creative Biolabs is proud to develop novel PD-L1-specific antibody from scratch to commercial IVD kit (we can also start with provided antibody candidates).

If you are interested in our IVD antibodies discovery services, please contact us for more details.


  1. Kythreotou, A., (2017) “PD-L1.” J Clin Pathol. 0:1-6.

Online Inquiry

*E-mail Address:
*Service & Products Interested:
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.

Contact Us

45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-381-2994
Fax: 1-631-207-8356

Follow us on:
Copyright ©2011 - 2019 Creative Biolabs.